3778-73-2

Applied Filters:

Keyword:'3778-73-2'

Showing 1-1 of 1 result for "3778-73-2" within Papers

A pilot study on reparixin, a CXCR1/2 antagonist, to assess safety and efficacy in attenuating ischaemia-reperfusion injury and inflammation after on-pump coronary artery bypass graft surgery.

P Opfermann et al.

Clinical and experimental immunology, 180(1), 131-142 (2014-11-18)

Reparixin, a CXCR 1/2 antagonist, has been shown to mitigate ischaemia-reperfusion injury (IRI) in various organ systems in animals, but data in humans are scarce. The aim of this double-blinded, placebo-controlled pilot study was to evaluate the safety and efficacy

Page 1 of 1